Christoph Driessen

Christoph Driessen


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in Nature
Verified
Journal Article
Open access
PDF file
ZSZdenek Skrott
Zdenek Skrott
MMMartin Mistrik
Martin Mistrik
KAKlaus Kaae Andersen
Klaus Kaae Andersen
SFSøren Friis
Søren Friis
DMDusana Majera
Dusana Majera
JBJiri Bartek
Jiri Bartek
Cancer incidence is rising and this global challenge is further exacerbated by tumour resistance to available medicines. A promising approach to meet the need for improved cancer treatment is drug repurposing. Here we highlight the potential for repurposing disulfiram (also known by the trade name Antabuse), an old alcohol-aversion drug that has been shown to be effective against diverse cancer types in preclinical studies. Our nationwide epidemiological study reveals that patients who continuously used disulfiram have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis. Moreover, we identify the ditiocarb–copper complex as the metabolite of disulfiram that is responsible for its anti-cancer effects, and provide methods to detect preferential accumulation of the complex in tumours and candidate biomarkers to analyse its effect on cells and tissues. Finally, our functional and biophysical analyses reveal the molecular target of disulfiram’s tumour-suppressing effects as NPL4, an adaptor of p97 (also known as VCP) segregase, which is essential for the turnover of proteins involved in multiple regulatory and stress-response pathways in cells.

13 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JDJoern Dengjel
Joern Dengjel
OSOliver Schoor
Oliver Schoor
RFRainer Fischer
Rainer Fischer
MRMichael Reich
Michael Reich
MKMarianne Kraus
Marianne Kraus
SSStefan Stevanovic
Stefan Stevanovic
MHC–peptide complexes mediate key functions in adaptive immunity. In a classical view, MHC-I molecules present peptides from intracellular source proteins, whereas MHC-II molecules present antigenic peptides from exogenous and membrane proteins. Nevertheless, substantial crosstalk between these two pathways has been observed. We investigated the influence of autophagy on the MHC-II ligandome and demonstrated that peptide presentation is altered considerably upon induction of autophagy. The presentation of peptides from intracellular and lysosomal source proteins was strongly increased on MHC-II in contrast with peptides from membrane and secreted proteins. In addition, autophagy influenced the MHC-II antigen-processing machinery. Our study illustrates a profound influence of autophagy on the class II peptide repertoire and suggests that this finding has implications for the regulation of CD4+T cell-mediated processes.

1 May 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SAShirin Arastu-Kapur
Shirin Arastu-Kapur
JAJanet L. Anderl
Janet L. Anderl
MKMarianne Kraus
Marianne Kraus
FPFrancesco Parlati
Francesco Parlati
KSKevin D. Shenk
Kevin D. Shenk
CKChristopher J. Kirk
Christopher J. Kirk
Purpose: Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. Carfilzomib, a tetrapeptide epoxyketone proteasome inhibitor, currently in clinical investigation in myeloma, is associated with low rates of PN. We sought to determine whether PN represents a target-mediated adverse drug reaction (ADR). Experimental Design: Neurodegenerative effects of proteasome inhibitors were assessed in an in vitro model utilizing a differentiated neuronal cell line. Secondary targets of both inhibitors were identified by a multifaceted approach involving candidate screening, profiling with an activity-based probe, and database mining. Secondary target activity was measured in rats and patients receiving both inhibitors. Results: Despite equivalent levels of proteasome inhibition, only bortezomib reduced neurite length, suggesting a nonproteasomal mechanism. In cell lysates, bortezomib, but not carfilzomib, significantly inhibited the serine proteases cathepsin G (CatG), cathepsin A, chymase, dipeptidyl peptidase II, and HtrA2/Omi at potencies near or equivalent to that for the proteasome. Inhibition of CatG was detected in splenocytes of rats receiving bortezomib and in peripheral blood mononuclear cells derived from bortezomib-treated patients. Levels of HtrA2/Omi, which is known to be involved in neuronal survival, were upregulated in neuronal cells exposed to both proteasome inhibitors but was inhibited only by bortezomib exposure. Conclusion: These data show that bortezomib-induced neurodegeneration in vitro occurs via a proteasome-independent mechanism and that bortezomib inhibits several nonproteasomal targets in vitro and in vivo, which may play a role in its clinical ADR profile. Clin Cancer Res; 17(9); 2734–43. ©2011 AACR.

1 July 2019 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
FBFiamma Berner
Fiamma Berner
DBDavid Bomze
David Bomze
SDStefan Diem
Stefan Diem
OAOmar Hasan Ali
Omar Hasan Ali
MFMirjam Fässler
Mirjam Fässler
LFLukas Flatz
Lukas Flatz
Cancer immunotherapy with checkpoint inhibitors has been reported to improve survival for patients with non–small cell lung cancer (NSCLC).1-3 However, the autoimmune toxic effects of checkpoint inhibitors are frequent, with immune-mediated adverse effects of any grade occurring in approximately 30% of patients and toxic effects of grade 3, 4, or 5 occurring in up to 10% of patients.1 The causes of these events remain elusive. We studied a prospective cohort of 73 patients with NSCLC receiving anti–PD-1 (programmed cell death 1) therapy to gain insight into the pathophysiologic processes of autoimmune skin toxic effects.

13 July 2016 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
KYKwee Yong
Kwee Yong
MDMichel Delforge
Michel Delforge
CDChristoph Driessen
Christoph Driessen
LFLeah Fink
Leah Fink
AFAlain Flinois
Alain Flinois
MCMichele Cavo
Michele Cavo
Summary: With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first‐line therapy was 6 months, followed by a median treatment‐free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician‐judged. Toxicities and co‐morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real‐world data provide an insight into patient outcomes and treatment decisions being made in clinical practice.

27 October 2011 in Blood
Verified
Journal Article
Closed access
PDF file
APAntonio Palumbo
Antonio Palumbo
SBSara Bringhen
Sara Bringhen
HLHeinz Ludwig
Heinz Ludwig
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
JBJoan Bladé
Joan Bladé
PSPieter Sonneveld
Pieter Sonneveld
Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.